Effects of genetic polymorphisms of drug transporter ABCB1 (MDR1) and cytochrome P450 enzymes CYP2A6, CYP2B6 on nicotine addiction and smoking cessation
A Muderrisoglu, E Babaoglu, ET Korkmaz… - Frontiers in …, 2020 - frontiersin.org
Frontiers in Genetics, 2020•frontiersin.org
Objectives To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6,
CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a
Turkish population. Methods 130 smokers and 130 non-smokers were recruited. Individuals
who never smoked were described as non-smokers. 130 smokers were treated with nicotine
replacement therapy (NRT)(n= 40), bupropion (n= 47), bupropion+ NRT (n= 15), and
varenicline (n= 28). Smokers were checked by phone after 12 weeks of treatment whether …
CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a
Turkish population. Methods 130 smokers and 130 non-smokers were recruited. Individuals
who never smoked were described as non-smokers. 130 smokers were treated with nicotine
replacement therapy (NRT)(n= 40), bupropion (n= 47), bupropion+ NRT (n= 15), and
varenicline (n= 28). Smokers were checked by phone after 12 weeks of treatment whether …
Objectives
To determine the effects of genetic polymorphisms of ABCB1 (MDR1), CYP2A6, CYP2B6 on smoking status, and clinical outcomes of smoking cessation therapies in a Turkish population.
Methods
130 smokers and 130 non-smokers were recruited. Individuals who never smoked were described as non-smokers. 130 smokers were treated with nicotine replacement therapy (NRT) (n = 40), bupropion (n = 47), bupropion + NRT (n = 15), and varenicline (n = 28). Smokers were checked by phone after 12 weeks of treatment whether they were able to quit smoking or not. Genotyping and phenotyping were performed.
Results
Cessation rates were as follows; 20.0% for NRT, 29.8% for bupropion, 40.0% for bupropion + NRT, 57.1% for varenicline (p = 0.013). The frequency of ABCB1 1236TT-2677TT-3435TT haplotype was significantly higher in non-smokers as compared to smokers (21.5% vs. 10.8, respectively; p = 0.018). Neither smoking status nor smoking cessation rates were associated with genetic variants of CYP2A6 (p = 0.652, p = 0.328, respectively), or variants of CYP2B6 (p = 0.514, p = 0.779, respectively).
Conclusion
Genetic variants of the drug transporter ABCB1 and the 1236TT-2677TT-3435TT haplotype was significantly associated with non-smoking status. Neither ABCB1 nor CYP2A6, CYP2B6 genetic variants were associated with smoking cessation rates at the 12th week of drug treatment.
Frontiers以上显示的是最相近的搜索结果。 查看全部搜索结果